These are the trials that are currently open in the Early Phase Unit (Last updated 18 January 2019).
| Trial Short Name | Molecular Target(s) | Patient Population | Lead Investigator(s) in Cambridge |
| AZD1390 | ATM with RT | Glioblastoma | S Jeffries / R Baird |
| AZD6738 combo with olaparib |
ATR/PARP | Gastric cancer (low ATM expression) & BRCA mutation/HRD high breast cancer |
D Jodrell |
| AZD9833 ORAL SERD | CDK4/6 | ER positive, HER2 negative advanced breast cancer | R Baird |
| Basket of Baskets | PD-L1 | Solid tumours with high mutational load/MSI | R Baird |
| BOS172722 | Monopolar spindle 1 kinase inhibitor | Solid tumours suitable for weekly taxol | B Basu |
| CALIBRATE | cfDNA evaluation | Patients on early phase clinical trials | R Baird / S Pacey |
| CALIBRATION | ctDNA evaluation | Advanced oesophageal malignancies | S Pacey |
| CamBMT1 phase II | EGFR/HER2 | Operable brain metastasis (breast/lung) | R Baird |
| CURIS | PD-1/PD-L1/VISTA | Mesothelioma with FDA approved immunotherapy option | S Pacey |
| iBET | Bromodomain | Haematologic malignancies | B Huntly |
| MOv18 IgE | IgE antibody/ α-FR | α-Folate receptor over-expressing gynaecological tumours | B Basu |
| OUTREACH | CEBPα | Hepatocellular carcinoma | B Basu |
| PATRIOT | ATR | Any tumour type – palliative radiotherapy combined with ATR inhibitor | R Baird |
| POSEIDON phase II | PI3K | HR+ metastatic breast cancer | R Baird |
| STARTRK2 | NTRK1/2/3 | Proven NTRK1/2/3 gene rearrangements | S Pacey |
| VAPER | hTERT | Advanced solid tumours | R Baird |